Last edition
News about "ti-interleukin-33 monoclonal antibody"
Tolerance Bio Licenses Anti-IL-33 Antibody TLB-33 from Tanabe Pharma
Tolerance Bio plans to advance TLB-33 into Phase 2 development to evaluate its potential in preserving thymic function and supporting immune resilience.
Ti-interleukin-33 Monoclonal Antibody | 29/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members